Education
About Us
Working with TipRanks
Follow Us
Globus Medical (GMED)
NYSE:GMED
GMED Stock Chart & Stats
$88.88
$2.66(3.19%)
At close: 4:00 PM EST
$88.88
$2.66(3.19%)
Day’s Range― - ―
52-Week Range$51.79 - $94.93
Previous CloseN/A
Volume442.39K
Average Volume (3M)2.09M
Market Cap
$11.82B
Enterprise Value$7.48B
Total Cash (Recent Filing)$390.52M
Total Debt (Recent Filing)$119.34M
Price to Earnings (P/E)28.7
Beta0.77
Next Earnings
Feb 19, 2026EPS Estimate
1.07Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.18
Shares Outstanding112,175,354
10 Day Avg. Volume1,295,333
30 Day Avg. Volume2,087,908
Financial Highlights & Ratios
PEG Ratio-3.60
Price to Book (P/B)2.69
Price to Sales (P/S)4.46
P/FCF Ratio27.70
Enterprise Value/Market Cap0.63
Enterprise Value/Revenue2.70
Enterprise Value/Gross Profit4.20
Enterprise Value/Ebitda10.42
Forecast
1Y Price Target
$96.40Price Target Upside8.46% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering12
EPS Forecast (FY)3.79
Revenue Forecast (FY)$2.89B
Bulls Say, Bears Say
Bulls Say
Financial Guidance And ProfitabilityGMED raised 2025 guidance on the top and bottom line inclusive of the Nevro acquisition, with Nevro now expected to be accretive to 2025 bottom line.
Product Launch And GrowthThe launch of new products like ExcelsiusXR and clearance of additional ExcelsiusGPS instruments is expected to support growth.
Revenue PerformanceGMED reported revenue of $769.0M, exceeding expectations by approximately $34.3M.
Bears Say
Capital Sales TimelinesEnabling technology capital sale timelines continue to drag: Despite the strong performance in other areas of the portfolio, GMED saw a 27% decline in its enabling technologies business as it continues to see elongated capital sales cycles.
Enabling Technologies Revenue DeclineEnabling Technologies saw revenue decline, driven by lower ExcelsiusGPS Robotic Systems sales.
Margin Expansion ChallengesDespite strong results, challenging comparisons and limitations on margin expansion suggest shares are fairly valued.
Globus Medical News
GMED FAQ
What was Globus Medical’s price range in the past 12 months?
Globus Medical lowest stock price was $51.79 and its highest was $94.93 in the past 12 months.
What is Globus Medical’s market cap?
Globus Medical’s market cap is $11.82B.
When is Globus Medical’s upcoming earnings report date?
Globus Medical’s upcoming earnings report date is Feb 19, 2026 which is in 67 days.
How were Globus Medical’s earnings last quarter?
Globus Medical released its earnings results on Nov 06, 2025. The company reported $1.18 earnings per share for the quarter, beating the consensus estimate of $0.781 by $0.399.
Is Globus Medical overvalued?
According to Wall Street analysts Globus Medical’s price is currently Undervalued.
Does Globus Medical pay dividends?
Globus Medical does not currently pay dividends.
What is Globus Medical’s EPS estimate?
Globus Medical’s EPS estimate is 1.07.
How many shares outstanding does Globus Medical have?
Globus Medical has 112,175,354 shares outstanding.
What happened to Globus Medical’s price movement after its last earnings report?
Globus Medical reported an EPS of $1.18 in its last earnings report, beating expectations of $0.781. Following the earnings report the stock price went up 35.942%.
Which hedge fund is a major shareholder of Globus Medical?
Currently, no hedge funds are holding shares in GMED
Globus Medical Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$96.40 (8.46% Upside)
$96.40 (8.46% Upside)
Blogger Sentiment
Bullish
GMED Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 352.9K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $4.3M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 3.5%
Last 30 Days ▲ 17.9%
Last 30 Days ▲ 17.9%
Technicals
SMA
Positive
20 days / 200 days
Momentum
7.16%
12-Months-Change
Fundamentals
Return on Equity
10.01%
Trailing 12-Months
Asset Growth
0.19%
Trailing 12-Months
Company Description
Globus Medical
Globus Medical, Inc., a medical device company, develops and commercializes healthcare solutions for patients with musculoskeletal disorders in the United States and internationally. It offers spine products, such as traditional fusion implants comprising pedicle screw and rod systems, plating systems, intervertebral spacers, and corpectomy devices for treating degenerative, deformity, tumors, and trauma conditions; treatment options for motion preservation technologies that consist of dynamic stabilization, total disc replacement, and interspinous distraction devices; interventional pain management solutions to treat vertebral compression fractures; and regenerative biologic products comprising of allografts and synthetic alternatives. The company also offers products for the treatment of orthopedic trauma, including fracture plates, compression screws, intramedullary nails, and external fixation systems; and hip and knee joint solutions, including modular hip stems and acetabular cups, as well as posterior stabilizing and cruciate retaining knee arthroplasty implants. In addition, it distributes human cell, tissue, and cellular and tissue-based products. Globus Medical, Inc. was incorporated in 2003 and is headquartered in Audubon, Pennsylvania.
GMED Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call for Globus Medical was predominantly positive, with significant revenue and earnings growth, successful integration of Nevro, and strong performances in the U.S. Spine and Trauma segments. Despite these successes, there were challenges in the Enabling Technologies segment, including a decline in revenue and slower capital sales. The company's ability to adapt to market conditions and its strong cash flow generation underscore a solid financial position.View all GMED earnings summariesGMED Net sales Breakdown
92.34% Musculoskeletal Solutions
7.66% Enabling Technologies
GMED Stock 12 Month Forecast
Average Price Target
$96.40
▲(8.46% Upside)
Technical Analysis
Boston Scientific
―
Koninklijke Philips
―
Smith & Nephew Snats
―
Stryker
―
Zimmer Biomet Holdings
―
Ownership Overview
0.58% Insiders
27.16% Mutual Funds
33.99% Other Institutional Investors
20.41% Public Companies and
Individual Investors